INMB INMUNE BIO INC Product Launches 8-K Filing 2023 - FDA Application for INKmune INmune Bio Inc. has submitted an investigational new drug application to the U.S. FDA for the use of INKmune to treat metastatic castration-resistant prostate cancer.Get access to all SEC 8-K filings of the INMUNE BIO INC